Frontiers in Cell and Developmental Biology (Dec 2021)

Hsa_circ_0062682 Promotes Serine Metabolism and Tumor Growth in Colorectal Cancer by Regulating the miR-940/PHGDH Axis

  • Shengbai Sun,
  • Shengbai Sun,
  • Chaoqun Li,
  • Chaoqun Li,
  • Kaisa Cui,
  • Kaisa Cui,
  • Bingxin Liu,
  • Bingxin Liu,
  • Mingyue Zhou,
  • Mingyue Zhou,
  • Yulin Cao,
  • Yulin Cao,
  • Jia Zhang,
  • Jia Zhang,
  • Zehua Bian,
  • Zehua Bian,
  • Bojian Fei,
  • Zhaohui Huang,
  • Zhaohui Huang

DOI
https://doi.org/10.3389/fcell.2021.770006
Journal volume & issue
Vol. 9

Abstract

Read online

Colorectal cancer (CRC) is one of the most common malignancies globally. Increasing evidence indicates that circular RNAs (circRNAs) play a pivotal role in various cancers. The present study focused on exploring the role of a functionally unknown circRNA, hsa_circ_0062682 (circ_0062682), in CRC. By online analyses and experimental validations, we showed that circ_0062682 expression was aberrantly increased in CRC tissues compared with paired normal tissues. Increased expression of circ_0062682 in CRC notably correlated with a poor prognosis and advanced tumor stage. Functional experiments showed that circ_0062682 knockdown reduced CRC growth both in vitro and in vivo. Mechanistically, we revealed that circ_0062682 could sponge miR-940 and identified D-3-phosphoglycerate dehydrogenase (PHGDH), a key oxidoreductase involved in serine biosynthesis, as a novel target of miR-940. Silencing miR-940 expression could mimic the inhibitory effect of circ_0062682 knockdown on CRC proliferation. The expression of PHGDH was downregulated in circ_0062682-depleted or miR-940 overexpressing CRC cells at both the mRNA and protein levels. Circ_0062682 knockdown suppressed CRC growth by decreasing PHGDH expression and serine production via miR-940. Taken together, these data demonstrate, for the first time, that circ_0062682 promotes serine metabolism and tumor growth in CRC by regulating the miR-940/PHGDH axis, suggesting circ_0062682 as a potential novel therapeutic target for CRC.

Keywords